PGG glucan(PGG glucan) - 药物靶点：CD11b x CD32A_在研适应症：乳腺癌_专利_临床

概要

基本信息

药物类型

聚合物

别名

Betafectin、Imprime、Imprime PGG

+ [4]

靶点

CD11b x CD32A

作用方式

激活剂、刺激剂

作用机制

CD11b激活剂(integrin subunit alpha M activators)、CD32A激活剂(低亲和力免疫球蛋白γFc区受体II-a激活剂)、免疫刺激剂

治疗领域

肿瘤皮肤和肌肉骨骼疾病

在研适应症

乳腺癌

非在研适应症

大肠腺癌晚期非小细胞肺癌复发性结直肠癌+ [6]

原研机构

Biothera Pharmaceuticals, Inc. (Delaware)

在研机构

HiberCell, Inc.初创企业

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

18

项与 PGG glucan 相关的临床试验

NCT05484011

/ Terminated临床1期

P1b, Open-Label, Safety, Tolerability, Efficacy Study of a Soluble Beta-glucan Odetiglucan in Combination w/ a CD40 Agonist (CDX-1140) in Patients w/ Metastatic Pancreatic Adenocarcinoma Whose Disease Did Not Progress During 1st-Line Chemo

The primary objective of this maintenance therapy study is to identify the maximum tolerated dose (MTD) and/ or recommended Phase 2 dose (RP2D), and evaluate the safety, tolerability, and dose-limiting toxicities (DLTs) of odetiglucan in combination with CDX-1140 in patients with metastatic PDAC with evidence of response or stable disease following a minimum of 16 and no more than 32 weeks of chemotherapy.
Up to 45 patients will be enrolled and dosed (30 patients in Part A and 15 in Part B).

开始日期2022-12-15

申办/合作机构

HiberCell, Inc.初创企业

[+1]

NCT05159778

/ Completed临床2期

A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With Metastatic Breast Cancer (mBCA) Who Have Progressed Through Prior Hormonal Therapy

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled.
The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

开始日期2021-11-09

申办/合作机构

HiberCell, Inc.初创企业

[+1]

CTRI/2021/10/037380

/ Not yet recruiting临床3期

An Open Label, Prospective, Randomized, Comparative, Multiple Arm Clinical Study to Evaluate the Immunomodulatory Efficacy of Nichi Glucan in Comparison with Conventional Therapeutic Regimen in Adult Subjects with Covid-19 caused by SARS-COV2 (B-COV)

开始日期2021-10-25

申办/合作机构-

100 项与 PGG glucan 相关的临床结果

登录后查看更多信息

100 项与 PGG glucan 相关的转化医学

登录后查看更多信息

100 项与 PGG glucan 相关的专利（医药）

登录后查看更多信息

21

项与 PGG glucan 相关的文献（医药）

2024-11-01·Translational Lung Cancer Research

Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017

Article

作者: Malhotra, Jyoti ; Mott, Sarah L ; Feldman, Lawrence ; Hulbert, Alicia ; Liu, Li ; Kennedy, Kathleen ; Furqan, Muhammad ; Pasquinelli, Mary M ; Shergill, Ardaman

BackgroundTherapeutic strategies to engage anti-tumor innate immunity are still underdeveloped. Imprime PGG (imprime), a pathogen-associated molecular pattern (PAMP), through pattern recognition receptors, successfully illicit a broad-based innate immune response in preclinical models against various cancers. We aimed to study safety and efficacy of imprime in combination with pembrolizumab in advanced stage non-small cell lung cancer (NSCLC).MethodsWe conducted an investigator-initiated, multi-institutional, single-arm, phase Ib/II trial in previously treated, advanced stage NSCLC patients. Primary endpoints were maximum-tolerated dose (MTD) of imprime for the phase Ib, and progression-free survival (PFS) for the phase II study (NCT03003468).ResultsAll 33 eligible patients were included in the safety analysis. No dose-limiting toxicity was observed and the imprime dose of 4 mg/kg was determined as the MTD. Thirty patients treated at the MTD (phase Ib, 6; phase II, 24) were included in the efficacy analysis. Median length of follow-up was 10.8 months. Confirmed objective response rate was 10% [95% confidence interval (CI): 2-27%], with one complete and two partial responses. Median PFS was 2.6 months (95% CI: 1.4-7.0), and 6- and 12-month PFS rates were 37% and 17%, respectively. Median overall survival (OS) was 11.1 months, and 6- and 12-month OS rates were 75% and 46%. Univariate analysis was performed to assess the impact of age, sex, race, disease-stage, programmed death-ligand 1 (PD-L1) expression levels, and prior immunotherapy on PFS and OS. Of these, prior immunotherapy negatively influenced OS [hazard ratio (HR): 2.95, 95% CI: 1.21-7.24]. Overall, the combination was safe and tolerable.ConclusionsThe combination of imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage NSCLC patients who previously progressed on anti-programmed death 1 (PD-1)/PD-L1 immunotherapies. Further investigation is needed to understand the effects of therapeutic PAMPs to mount a strong innate immune response against cancer.

2020-03-01·Anticancer Research4区 · 医学

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

4区 · 医学

Article

作者: Rathmann, Blaine ; Jha, Gautam ; Qiu, Xiaohong ; Bose, Nandita ; Hurley, Peter J ; Gargano, Michele ; Harrison, Ben ; Gorden, Keith ; Dudek, Arkadiusz Z ; Ottoson, Nadine

BACKGROUNDBTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum is necessary for BTH1677 antitumoral activity. We hypothesized that infusion of immunoglobulin can reinstate responses to BTH1677 in individuals with low ABA levels.PATIENTS AND METHODSWe report two single-patient studies: one in a patient with metastatic colorectal cancer who received BTH1677, combined with tumor targeting antibody cetuximab; and a second in a patient with metastatic neuroendocrine tumor who received BTH1677 combined with immune checkpoint inhibitor pembrolizumab.RESULTSThe patients had low serum titers of ABA and low innate immune effector functionality induced by BTH1677. Addition of intravenous immunoglobulins restored innate immune activity of BTH1677 and induced clinically meaningful anti-tumoral activity, with long-term disease control.CONCLUSIONInfusion of immunoglobulin can restore activity of BTH1677 in individuals with low serum ABA level.

2019-05-15·The Journal of Immunology2区 · 医学

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

2区 · 医学

Article

作者: Lowe, Jamie R ; Rathmann, Blaine T ; Ottoson, Nadine R ; Uhlik, Mark T ; Fulton, Ross B ; Jordan, Lindsay R ; Graff, Jeremy R ; Harrison, Ben ; Chan, Anissa S H ; Fraser, Kathryn A ; Bose, Nandita ; Ertelt, Kathleen E ; Gorden, Keith B ; Jonas, Adria Bykowski ; Leonardo, Steven M ; Qiu, Xiaohong ; Walsh, Richard M ; Kangas, Takashi O ; Huhn, Richard D ; Matson, Mark A

AbstractImprime PGG (Imprime) is an i.v. administered, yeast β-1,3/1,6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan Abs (ABA). We administered Imprime to healthy human volunteers to assess the necessity of ABA for Imprime-mediated immunopharmacodynamic (IPD) changes. Imprime (4 mg/kg) was administered i.v. in single and multiple infusions. Subsets of subjects were premedicated with antihistamine and corticosteroid. Peripheral blood was measured before, during and after Imprime administration for IPD changes (e.g., ABA, circulating immune complexes, complement activation, complete blood counts, cytokine/chemokine, and gene expression changes). IPD changes were analyzed based on pretreatment serum ABA levels: low-ABA (<20 μg/ml), mid-ABA (≥20–50 μg/ml), and high-ABA (≥50 μg/ml). At the end of infusion, free serum ABA levels decreased, circulating immune complex levels increased, and complement activation was observed. At ∼1–4 h after end of infusion, increased expression of cytokines/chemokines, a 1.5-4-fold increase in neutrophil and monocyte counts and a broad activation of innate immune genes were observed. Low-ABA subjects typically showed minimal IPD changes except when ABA levels rose above 20 μg/ml after repeated Imprime dosing. Mild-to-moderate infusion-related reactions occurred in subjects with ABA ≥20 μg/ml. Premedications alleviated some of the infusion-related reactions, but also inhibited cytokine responses. In conclusion, ABA levels, being critical for Imprime-mediated immune activation may provide a plausible, mechanism-based biomarker to identify patients most likely to respond to Imprime-based anticancer immunotherapy.

9

项与 PGG glucan 相关的新闻（医药）

2024-10-23

·BioSpace

HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia. The FDA’s Fast Track program aims to facilitate the development, and expedite the review, of novel potential therapies that are designed to treat serious conditions and have the potential to address significant unmet medical need. “We are proud to announce the grant of Fast Track designation by the FDA,” said Jonathan Lanfear, President & CEO of HiberCell. Receiving Fast Track designation highlights the FDA’s recognition of the robust preclinical data generated to date for HC-7366 and the potential for HC-7366 to address the significant unmet need that exists in R/R AML.” Mr. Lanfear continued, “HC-7366 was the first GCN2-activator to enter the clinic in AML and is the only GCN2-targeting agent to receive Fast Track designation for the treatment of AML, validating our preclinical and translational efforts. We plan to leverage the Fast-Track designation to work closely with the FDA to facilitate and, potentially accelerate the development of HC-7366 in AML.” HC-7366 is currently under clinical investigation in both solid and liquid tumor settings. The Phase 1b study in AML (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in relapsed/refractory (R/R) AML or MDS AML. This study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in a R/R AML population. Dependent on observations in the dose escalation portion, this study may include additional combination and monotherapy expansions. About HC-7366 HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with standard of care agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in R/R AML (NCT06285890). About HiberCell HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. For Media/Investor Inquiries: IR@hibercell.com

临床1期快速通道临床2期

2024-05-29

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)

May 28, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML). "We are excited to announce the first patient dosed in this study," said Jonathan Lanfear, President & CEO of HiberCell. "This study builds on the preclinical data we have presented at recent conferences, including the 2023 ASH Annual Meeting and Exposition, which support evaluation of HC-7366 in combination with venetoclax and azacitidine in AML patients with significant unmet need." The study’s principal investigator is Dr. Abhishek Maiti, assistant professor of Leukemia at The University of Texas MD Anderson Cancer Center. Mr. Lanfear continued, "The initiation of this study along with our recently announced study of HC-7366 in clear cell renal cell carcinoma marks the continued advancement of HC-7366 and HiberCell. These are seminal combinatorial studies of HC-7366 with the potential to address large, targeted, and underserved patient populations. We look forward to seeing data for these studies throughout 2024 and 2025." The newly announced Phase 1b study (NCT06285890) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with standard dosing of venetoclax and azacitidine in patients with relapsed/refractory (R/R) AML or MDS AML. The study aims to determine the recommended Phase 2 dose (RP2D) of HC-7366 in combination with venetoclax and azacitidine in a R/R AML population. The study will enroll up to 18 patients. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in both solid and liquid tumor models. HC-7366 is currently under clinical development in a Phase 1b/2 study in clear cell renal cell renal cell carcinoma in combination with belzutifan (NCT06234605) and in a Phase 1b study in AML in combination with azacitidine and venetoclax (NCT06285890). HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address advanced cancer and cancer resistance. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床研究临床2期

2024-05-02

·GlobeNewswire-Health Care

HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

May 01, 2024 -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC). The Phase 1b study (NCT06234605) will evaluate the safety, tolerability, and preliminary efficacy of HC-7366 in combination with belzutifan in patients with advanced ccRCC. This trial will also determine a recommended Phase 2 dose (RP2D) of HC-7366 in combination with fixed-dose belzutifan, 120 mg po qd. Dose escalation of HC-7366 in the combination, followed by an expansion phase will optimize dose evaluation. An independent HC-7366 monotherapy cohort is being evaluated in parallel. The study will enroll up to 80 patients at clinical sites across the US. Robert J. Motzer, MD., Section Head, Kidney Cancer, Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center (MSK) will be the lead Principal Investigator (PI) for the clinical trial. "The first patient dosed in this trial marks the beginning of an exciting new chapter in the clinical development of HC-7366," stated Cherry Thomas, M.D., Chief Medical Officer. "The combination of HC-7366 with belzutifan, a key agent for the treatment of clear cell renal cell carcinoma, offers a potentially promising novel and differentiated treatment in a setting with major unmet need and limited treatment options for patients. We recently presented key aspects of the significant preclinical data in support of the combination at the 2024 American Association for Cancer Research Annual Conference." WELIREG® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. HC-7366 is a first-in-class, first-in-human, selective, potent, small molecule activator of the general control nonderepressible 2 (GCN2) kinase. GCN2 is one of the kinases of the integrated stress response (ISR) family, which responds to amino acid deprivation and is a key metabolic stress sensor in cells. While cancer cells utilize the ISR for survival, prolonged or hyperactivation of GCN2 with HC-7366 has been shown to have antitumor and immunomodulatory activity as a monotherapy and in combination with SOC agents in preclinical models of both solid and liquid tumors. HC-7366 is currently under clinical development in a Phase 1b study in clear cell renal cell carcinoma in combination with belzutifan. HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and antitumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both having completed Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently advancing towards Phase 2 clinical development, modulates the antitumor innate immune response. For more information about HiberCell, please visit hibercell.com. The content above comes from the network. if any infringement, please contact us to modify.

临床2期AACR会议

100 项与 PGG glucan 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性惰性非霍奇金淋巴瘤	临床1期	美国	HiberCell, Inc.初创企业	2014-12-01
难治性惰性非霍奇金淋巴瘤	临床1期	美国	HiberCell, Inc.初创企业	2014-12-01
KRAS 野生型结直肠癌	临床1期	法国	HiberCell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床1期	德国	HiberCell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床1期	波多黎各	HiberCell, Inc.初创企业	2011-04-01
KRAS 野生型结直肠癌	临床1期	美国	HiberCell, Inc.初创企业	2011-04-01
晚期非小细胞肺癌	临床1期	德国	HiberCell, Inc.初创企业	2009-08-01
晚期非小细胞肺癌	临床1期	美国	HiberCell, Inc.初创企业	2009-08-01
大肠腺癌	临床1期	菲律宾	HiberCell, Inc.初创企业	2007-10-01
复发性结直肠癌	临床1期	菲律宾	HiberCell, Inc.初创企业	2007-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03003468 (BTCRC LUN 15-017, Pubmed \| Transl Lung Cancer Res)	临床1/2期	非小细胞肺癌	33	Imprime PGG 4 mg/kg + Pembrolizumab	(積艱襯遞顧窪窪壓淵憲) = 淵窪夢網醖襯製積鏇齋顧遞窪衊夢範顧構壓鑰 (衊繭積夢蓋願構鹽壓獵 ) 更多	不佳	2024-11-01
NCT03003468 (BTCRC-LUN15-017 \| BTCRC LUN 15-017, CTgov)	临床1/2期	转移性非小细胞肺癌	35	Imprime PGG+pembrolizumab (Phase Ib)	獵遞鏇淵膚襯選積廠鏇(齋選窪艱糧觸獵鬱襯廠) = 選醖餘築鹽鹽餘淵獵衊構窪繭獵衊憲築獵餘鹹 (製鏇醖製糧蓋選築憲範, 鏇鬱鬱積構繭膚構築醖 ~ 憲鏇築膚糧餘選觸廠鹽) 更多	-	2024-08-13
				PGG (Imprime PGG 4 mg/kg)	(顧夢鹹餘廠蓋遞積積顧) = 淵廠觸繭顧遞窪鏇淵憲壓壓選鹽網膚餘窪簾鬱 (醖顧壓糧衊鏇範餘獵遞, 鏇獵衊齋觸蓋繭窪範蓋 ~ 選鑰觸醖蓋觸築鹽鑰選) 更多
NCT02981303 (Phase 2 \| IMPRIME 1, CTgov)	临床2期	肿瘤转移 \| 三阴性乳腺癌 \| 黑色素瘤 \| 局部晚期黑色素瘤	64	Imprime PGG+pembrolizumab (Melanoma)	餘觸鑰觸繭遞蓋顧築網(顧範網壓襯餘構鑰膚醖) = 繭構鹽鏇願繭鏇鬱獵積淵夢繭壓構繭鏇鏇廠積 (觸壓糧鏇廠醖選蓋窪遞, 衊簾窪襯蓋鏇鹽積築廠 ~ 繭憲憲繭遞鏇簾鏇構齋) 更多	-	2024-07-09
				Imprime PGG+pembrolizumab (Triple Negative Breast Cancer)	餘觸鑰觸繭遞蓋顧築網(顧範網壓襯餘構鑰膚醖) = 觸構範淵鹹糧膚衊願遞淵夢繭壓構繭鏇鏇廠積 (觸壓糧鏇廠醖選蓋窪遞, 艱壓蓋繭齋選鹹壓淵廠 ~ 製淵廠繭範夢艱簾顧積) 更多
NCT03555149 (MORPHEUS, CTgov)	临床1/2期	转移性结直肠癌	96	Regorafenib (Regorafenib (Control))	(顧衊餘網構鹽憲選築選) = 繭獵構壓廠構夢範壓簾範製憲構製網壓鏇鹹獵 (醖獵襯糧鬱廠鏇醖鹽襯, 醖糧鬱製齋簾憲簾壓獵 ~ 蓋製鏇鹹鹹鹽窪廠築醖) 更多	-	2023-11-07
				Imprime PGG+Atezolizumab+Bevacizumab (Atezolizumab + Imprime PGG + Bevacizumab)	(顧衊餘網構鹽憲選築選) = 醖膚窪遞鏇醖製願築繭範製憲構製網壓鏇鹹獵 (醖獵襯糧鬱廠鏇醖鹽襯, 選艱憲鹹蓋醖憲醖膚遞 ~ 糧鏇醖願網壓憲遞艱遞) 更多
NCT05159778 (ASCO2022)	临床2期	转移性乳腺癌	47	Odetiglucan 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk	(觸艱憲窪艱齋顧窪鏇襯) = 遞鹽網膚淵襯膚壓鬱鏇鹽蓋製築淵鑰鹹壓餘範 (積鑰願壓網憲鬱網觸網 ) 更多	-	2022-06-02
NCT03003468 (BTCRC-LUN15-017, WCLC2021 \| WCLC2021) 人工标引	临床1/2期	非小细胞肺癌	35	Pembro+Imprime PGG (phase Ib)	(積鹹淵衊選簾糧糧獵糧) = 淵願願願簾製製淵壓糧淵製築餘糧糧窪淵蓋簾 (醖網夢壓構築鑰衊構齋, 1.28 ~ 27.8) 更多	不佳	2021-09-08
				Pembro+Imprime PGG (phase II)	(積鹹淵衊選簾糧糧獵糧) = 襯鏇構蓋選網繭鹽艱構淵製築餘糧糧窪淵蓋簾 (醖網夢壓構築鑰衊構齋, 1.35 ~ 5.13) 更多
NCT03555149 (MORPHEUS, ASCO2021)	临床2期	转移性微卫星稳定结直肠癌	94	Atezolizumab + Imprime PGG + Bevacizumab	(廠壓襯壓鑰範範衊鹽衊) = 範獵鏇餘構簾選糧選鏇壓鹽獵壓壓選製鏇觸蓋 (窪鏇顧夢鹽製廠醖蓋艱, 4.4 ~ 10.5) 更多	-	2021-05-28
				Regorafenib	(廠壓襯壓鑰範範衊鹽衊) = 廠獵顧鹽鏇範醖衊鬱鏇壓鹽獵壓壓選製鏇觸蓋 (窪鏇顧夢鹽製廠醖蓋艱, 4.8 ~ NE) 更多
NCT02086175 (CTgov)	临床2期	难治性惰性非霍奇金淋巴瘤 \| 复发性惰性非霍奇金淋巴瘤	25	Imprime PGG+Rituximab	(顧襯遞壓繭衊醖醖蓋醖) = 衊鹹構構鏇繭製獵簾憲醖觸蓋餘築選選襯觸網 (鑰鏇製醖鬱顧夢構網餘, 衊顧鑰廠積醖膚選製觸 ~ 醖餘淵廠壓顧醖願窪壓) 更多	-	2021-01-07
NCT02981303 (IMPRIME 1, AACR2020)	临床2期	转移性三阴性乳腺癌	44	Imprime PGG + Pembrolizumab	(餘積範廠積襯遞壓選積) = 衊夢積積簾夢範襯網憲鹽獵構餘製積廠築襯顧 (願獵鏇鬱遞餘壓觸簾襯, 7.9 ~ 29.4) 更多	积极	2020-08-15
NCT02981303 (Phase 2, SITC2020)	临床2期	转移性黑色素瘤	20	Imprime PGG (Imprime)	網衊淵簾憲齋獵願顧選(鹹觸構觸範餘窪餘願觸) = 遞積鏇鏇廠築襯襯鑰艱築蓋糧窪淵襯遞襯糧築 (選襯鏇糧憲遞鬱範繭鹽 ) 更多	积极	2020-04-15